Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Two pre grant applications filed.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
"
[0026] Other than molecular weight and amino acid composition, which are specified in the approved label for the product, the label and other available literature for Copaxone.RTM. does not provide detailed information about the physiochemical characteristics of the product. Based on detailed characterization of the product and process kinetics, the inventors have unexpectedly found a signature component of GA, L-pyro-Glutamic Acid (pyro-Glu) GA, that can be evaluated to assess the GA manufacturing process and product quality. In particular, evaluation of pyro-Glu content can identify differences in materials that are not observed by looking at molar mass and amino acid composition alone. By evaluating the pyro-Glu content of a sample of a copolymer, e.g., GA, one can identify non-conforming copolymer compositions. Accordingly, pyro-Glu content can be used to evaluate product and process quality for GA. “
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=3&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
"[0053] In another aspect, the invention features a method of producing a recombinant therapeutic antibody preparation (e.g., abciximab, adalimumab, alemtuzumab, basiliximab, bevacizumab, certolizumab, cetuximab, daclizumab, eculizumab, efalizumab, gemtuzumab, ibritumomab, infliximab, muromonab-CD3, natalizumab, omalizumab, palivizumab, panitumumab, ranibizumab, rituximab, tositumomab, or trastuzumab), the method comprising: (a) providing a target value (e.g., a predetermined pharmaceutical product specification or a quality control criterion for a pharmaceutical preparation, e.g., a Certificate of Analysis (CofA), a Certificate of Testing (CofT), or a Master Batch Record of a reference therapeutic antibody product) of one or more of fucosylated glycans, galactosylated glycans, high mannose glycans (e.g., HM3, HM4, HM5, HM6, HM7, HM8, HM9, or combinations thereof), and sialylated glycans; (b) providing a CHO cell genetically engineered to express a recombinant antibody; (c) culturing the cell in a culture medium comprising putrescine (e.g., about 0.01 mg/L, 0.05 mg/L, 0.1 mg/L, 0.2 mg/L, 0.3 mg/L, 0.4 mg/L, 0.5 mg/L, 0.6 mg/L, 0.7 mg/L, 0.8 mg/L, 0.9 mg/L, 1 mg/L, 1.5 mg/L, 2 mg/L, 2.5 mg/L, 3 mg/L, 3.5 mg/L, 4 mg/L, 4.5 mg/L, 5 mg/L, 5.5 mg/L, 6 mg/L, 6.5 mg/L, 7 mg/L, 7.5 mg/L, 8 mg/L, 8.5 mg/L, 9 mg/L, 9.5 mg/L, 10 mg/L, 15 mg/L, 20 mg/L, 25 mg/L, 30 mg/L, 35 mg/L, 40 mg/L, putrescine) under conditions in which the cell expresses the recombinant antibody; (d) harvesting (e.g., purifying or isolating from the cell and/or culture medium) a preparation of the recombinant antibody produced by the cell; and (e) formulating (e.g., one or more of formulating, filling into a container, labeling, packaging) the preparation into a drug product if the preparation meets the target value of the one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans. “
Boing X 2
Two new pre grant patent applications.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=3&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
I like this one,
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=4&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
Boing X 2
Pre Grant Patent Application
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=2&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
"
[0126] Orencia.TM. (abatacept) is a soluble fusion protein that consists of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Abatacept is produced by recombinant DNA technology in a mammalian cell expression system. The apparent molecular weight of abatacept is 92 kilo Daltons. Abatacept is used to treat the symptoms of rheumatoid arthritis, to slow the progression of joint damage, and to improve physical function. The large complexity of this biotherapeutic arising from its heavy glycosylation (3 N-linked and two O-linked glycosylation sites) requires careful production and characterization. Since different modifications to the protein chemical composition (protein backbone modifications, glycosylation, etc.) can affect the biological function of the glycoprotein, it is important to ensure a good control over the chemical and physical properties of this biotherapeutic during manufacturing. "
jborg,
According to this, top line data.
http://finance.yahoo.com/news/momenta-pharmaceuticals-announces-top-line-201627461.html
Boing X 2
Few investors are talking about or know about this potential.
"Fast track status is granted to candidates that are being developed as treatments for serious health conditions and are considered to have the potential to fulfill an unmet medical need. This designation facilitates the development of such candidates and expedites its review process. Moreover, a candidate with fast track designation may become eligible for priority review or receive accelerated approval in the U.S. Additionally, the FDA may consider portions of the marketing application for review before the complete submission of the application.
With fast track status for necuparanib, Momenta can now interact with the FDA often for discussing various issues including the study design, the required level of data regarding safety of the candidate to support its approval and the structure and content of a new drug application. Necuparanib also has orphan drug designation in the U.S. for the treatment of pancreatic cancer. "
There were 46,000 new cases of metastatic pancreatic cancer in 2014 and likely there was many or more in 2015. 2016 will likely see that many new cases. The longer it takes for approval the more people will likely die without an opportunity to possible extend their life.
If the next phase results are as good as the first phase i can see where the FDA might push this to the front. With necuparanib being heparin based, it is likely much less dangerous than the drugs it is being combined with in the trials.
Only half the people are getting the drug and the other half the placebo. That likely leaves 45,000 plus a year that are not getting the benefit of potentially extending their lives. We are the sole owner of this drug so early approval likely will help the future patients as well as MNTA from the profit standpoint on not having to share on this drug. Just the cost of producing and detailing the drug.
These might well be very key words. "Additionally, the FDA may consider portions of the marketing application for review before the complete submission of the application.”
Here is hoping the next phase is even better than the first phase positive results. If they are as good or better I would be pounding on the FDA's door if I were one of the 46,000 new patients.
Sad to say, it is likely a shame and too late for the 2014 patients and some of the 2015 and 2016 patients. We lost a friend within the last six months that could not get a chance to try the drug. I told his wife the day of the orphan drug status approval but, he got the disease too early to be enrolled in a study.
May 2nd oral hearing coming up on Copaxone. Favorable ruling there and FDA approval sets us up for Jan 28th 2017.
We are now in that hard to get to Phase 111 on Humira with Shire.
Mylan deal on six new drugs along with major cash flow. 45M within less than 30 days and another 60M this year and next year per Craig.
Boing X 2
Pre Grant Patent Publication
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
"[0004] The present disclosure provides methods for assessing (e.g., measuring, analyzing, detecting, determining, evaluating, and/or estimating) the secondary structure of Glatiramer Acetate (GA) and, in some instances polymeric precursors of GA. The methods entail assessing the fraction of a sample of GA that is in alpha-helical conformation and/or assessing the fraction of a sample of GA that is in random coil conformation. The methods can be used, for example, for the selection of GA (e.g., upon completion of a manufacturing process) and/or polymeric precursors of GA (e.g., during a manufacturing process); to determine or confirm compliance of GA and/or polymeric precursors of GA with industrial and/or regulatory standards; to assess or confirm manufacturing consistency; as a quality control standard for use during manufacturing and/or against GA. Additional applications will be apparent to those of skill in the art based on the disclosure herein.”
Note last sentence.
Boing X 2
Momenta will webcast its presentation at two upcoming investor conferences.
http://finance.yahoo.com/news/momenta-pharmaceuticals-webcast-presentation-two-130000506.html
Boing X 2
Patent filing,
http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20151222&CC=BR&NR=PI0912277A2&KC=A2#
Filed 12/22/15
The invention allows for the production of oligosaccharide structures, e.g., a decasaccharide, having defined structure and/or properties. The invention provides for oligosaccharide drugs and drug candidates, e.g., drugs or drug candidates having a desired biological property, e.g., anti-factor Ha activity, anti-factor Xa activity, antithrombotic activity, anti-inflammatory activity, anti-angiogenic activity, anti-cancer or anti -metastatic activity. Preparations of the oligosaccharides, e.g., preparations of oligosaccharide drugs, can have optimized heterogeneity and can, e.g., be less heterogeneous than oligosaccharide drugs prepared from natural sources. The invention also provides libraries and other constructs useful for the production of oligosaccharides.
Boing x 2
pollyvonwog,
Don't worry. Damages for loss of use of our money continue to accrue along with bond costs and fees if we prevail.
It would be nice to get use of that 20M this year. As that 20M becomes more important this year the damages add up higher.
Boing X 2
pollyvonwog,
If Amphastar has admitted they will not collect on our bond, we should be moving to have the bond dismissed. It will only add to our damages if they then fight the dismissal.
It would free up 20M of cash that has been set aside and the costs associated with the bond. I would make a case for recovery of our bond costs and legal fees to date.
I agree with you things have the potential of looking up shortly. Two hearings within 4 months, that if ruled favorably, and with FDA approval, we are off to the races on 3x Copaxone in January of 17.
This one thing with our gaining share of the 20mg market and Mylan cash could keep us liquid. CW almost alluded to that when asked about future financing. Agreed, Sandoz needs to chip away faster this year.
I think we gain market share as the drug contracts keep coming up for renewal this year. We should start to see numbers traction growing shortly IMHO. If we can get to 2K scripts a week on the 20mg by the end of this year, and with 3x approval, we should sky rocket next year.
Once we can cover our quarterly cost with no additional financing we are almost there.
If we get to 2019, without further financing, which IMHO I think could well happen, we are off to the races with a product reaching market each year there after. 3X approval and market share could get us there fast.
We still have had no figuring in on our price for a potential recovery against Amphastar and Activis. With some additional luck, that will come. Damages continue to mount. We should now have better odds than the powerball.
Thank you for your updating the board on weekly scripts.
Boing X 2
marthambles,
Just that they are excited about the new FC n. starting Phase 1.
Many potential interchangeable diseases. Not a lot of time otherwise. They were on a pretty strict time to complete their portion. The slides show the list when you have time to review. Can also hear first hand least I make any mistakes. It will be on the MNTA site for a while. Good weekend or late night listen.
Short comments on Necuparanib and that they were only 3 months behind on their time line and are back on track. There was no problem with the drug it was the review board that wanted the potential covered best of my recollection.
Don't hold me on the spelling but I think the China company sounded like Woo Shee?
There was a slight pause between CW and the slides and the Q&A.
He had his chief medical officer with him on the Q&A.
Boing X 2
From the JPM conference this am.
Our Orencia in the lead against others. Not many other competitors in this field. 2BL market. Phase 1
Humira 13 indications in US and 9 indications in other countries.Phase 3 With target date of 18/19 to market.Should see clarification on patent issues prior.
Continuing to get new patients on Glatopa. As new drug contracts are renewed, where discounts are being given by TEVA, we should see sales increase. Their price increase might also help us. My words on price increase. 30% of 20mg market and growing. Getting more of the new patients.
Expecting to launch in 3x in quarter 5. Feb.hearing. 18 days until next month. My words again. Expect ours will be only one with fully interchangeable rating. Another hearing on May 2nd not mentioned.
By 2019 we will be bringing a product to market every year going forward.
Will see what happens on Humira with Shire taking over Baxter. If they give it back it is a neutral to a win as we are in Phase 111. If not it goes forward with Shire. CW said we will see what happens. We are in a good position either way. My words.
They have 7/8 competitors but we are going for interchangeability.
CW was on a recent FDA meeting. Another coming up shortly. Trying to tie down Flex Mfg. Size of batches FDA wants. very costly if they want 10 20k liter batches that can’t be used as product and ends up being chucked. Cost like 50M on a complex drug. Some only require 10 2k liters. Big difference. Will try to get the FDA to go along with less. Has hope they will to help keep cost of drugs down.
We have the new FLEX Mfg in China building a big plant to meet our needs if Mylan agrees to use them on some products.
Spending special attention to patent dance and IPR process to get the legal strategy right.
Mylan the best fit as they have agreed with our positions over the last several years and are on the same side with us going to the FDA.
More but this is the best I could keep up with on my notes.
Boing X 2
New Pre Grant patent application,
ANALYSIS OF AMINO ACID COPOLYMER COMPOSITIONS
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=8&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
Brilliant move,
"[0027] Other than molecular weight and amino acid composition, which are specified in the approved label for the product, the label and other available literature for Copaxone.RTM. does not provide detailed information about the physiochemical characteristics of the product. Based on detailed characterization of the product and process kinetics, the inventors have unexpectedly found a signature component of GA, L-pyro-Glutamic Acid (pyro-Glu) GA, that can be evaluated to assess the GA manufacturing process and product quality. In particular, evaluation of pyro-Glu content can identify differences in materials that are not observed by looking at molar mass and amino acid composition alone. By evaluating the pyro-Glu content of a sample of a copolymer, e.g., GA, one can identify non-conforming copolymer compositions. Accordingly, pyro-Glu content can be used to evaluate product and process quality for GA. “
Even more support for our 3X a week approval.
Boing X 2
Thank you Polly for posting the numbers.
Note the Express Scripts 2016 formulary list.
Effective Jan 1st 2016. I could not copy this list.
"Note page 1, glatopa Preferred drugs listed in small type.
Note on the bottom of page 3,
Tier 3 COPAXONE 3 times a week NON PREFERRED BRAND NAMED PRODUCTS IN BOLD, ITALIC LETTERS" as shown on page 1.
I suspect there should shortly be a C change on scripts. This is just Jan 5th. The Holiday week doesn’t concern me so much.
I am looking for the figures for Jan and going forward.
Boing X 2
As Dew said,
"USPTO IPR re Teva’s 40mg patents on 5/2/16;
~80% of patents subject to IPR are invalidated."
That is 4 months from today on Monday.
Boing X 2
A New Patent Application filed,
“abatacept is the generic, compendial, nonproprietary, or official FDA name for the product marketed in the United States as ORENCIA.RTM.”
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=5&f=G&l=50&co1=AND&d=PG01&s1=momenta&OS=momenta&RS=momenta
Boing X 2
Correction,
Search the last week not last 24 hours.
Boing X 2
Investopedia article
Lists MNTA as one of the top 5 Biotech stocks for 2016.
Can’t print due to copyright. A search for the last 24 hours will find the article.
Boing X 2
A new patent filing for M402.
Might want to read this one close. Includes tx of Malaria and a dozen other types of cancers without counting them all.
http://worldwide.espacenet.com/publicationDetails/description?CC=AU&NR=2014274377A1&KC=A1&FT=D&ND=3&date=20151112&DB=worldwide.espacenet.com&locale=en_EP
Boing X 2
pollyvonwog,
Thank you for the numbers.
I find it interesting that Copax NRX numbers have steadily decreased over three weeks. -286 over a three week period. Going down almost 100 a week.
I suspect we grow faster after Jan 1st.
Boing X 2
I just bought the domains for HSIVIG.com and the following for our family.
HSIVIG.Net,
HSIVig.Org and
HSIVig.info
I could not believe MNTA did not scoop these up.
Necuapanib was already taken.
I did this for MNTA second and our family first. With 56 potential drug approval I did not want a partner or anyone else grabbing this.
Imagine my wife’s reaction, when I laid this on her in a few minutes. She went with it and it and we tied it down. Yes, we can renew.
Boing X 2
mouton29,
Thank you for that information.
I note that as of 11/13 the shares short dropped to 5,788,778 the lowest is the last year.
Boing X 2
DewDilligence,
I sure hope our attorney's remember to add Teva to the litigation after the deal closes.
We don't want to take any chances with all the dollars at stake. That would be a major mess if they forgot to add them.
Boing X 2
Glotopa
Our United Healthcare Plan is being changed next year. It is for a very large company for their retirees.
My early morning read of covered drugs showed the following.
Glatopa is listed as Tier 1 while Copaxone is listed at Tier 3.
I suspect we will see more of that in 2016 and will likely see that for 40MG when approved.
Boing X 2
Someone spent more than pocket change after hours.
http://www.nasdaq.com/symbol/mnta/after-hours
13K+
The shares are drying up. I expect less shares will be selling in the $18 range. Has anyone noticed the decrease in the float this last quarter. Less that 7.7M shares. I suspect that is already lower with Oct. and Nov. 62M out of 69M owned. I hope they lock fingers on selling. The question I don't know is how many shares us peons own of the 7.7M . I hope it is a bunch.
Time will tell.
Boing X 2.
Still on track for partnership by end of the year.
Rick Shea just said of the cc today they were still on track for 50% sharing partnership by end of the year.
Another cc tomorrow.
29 actual working days left.
Boing X 2
Two new patent applications,
1. "GLYCOSYL TRANSFERASE FROM CHINESE HAMSTER AND RELATED METHODS
http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20151023&CC=IN&NR=3353DEN2012A&KC=A
Claims don’t appear to be available yet.
PHARMACEUTICAL COMPOSITIONS
http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=1&ND=3&adjacent=true&locale=en_EP&FT=D&date=20141204&CC=CA&NR=2910837A1&KC=A1
Claims available.
"http://worldwide.espacenet.com/publicationDetails/claims?CC=CA&NR=2910837A1&KC=A1&FT=D&ND=3&date=20141204&DB=worldwide.espacenet.com&locale=en_EP”
Boing X 2
Another new buyer.
SECTOR GAMMA AS as of 9/30/2015 added 350,920 shares of Momenta.
Boing X 2
tony111,
I agree.
If they should file an appeal,I would be requesting they post an appeal bond for all costs and fees should they not prevail. Especially, in light of the judges words of "manifestly unjust to MNTA" as well as the the AG opinion.
They could well open up a can of worms on an appeal in even a stronger opinion. Courts don't like frivolous appeals. Just my opinion.
Boing X 2
Double_Bagel
There was a lot of price competition mentioned so, I have no guess. They say we didn't make much of a profit. I likewise find it hard to believe that Sandoz would have 20 M in expenses if they sold that much.
We might get a better feel with the year end reporting which is much more detailed.
Boing X 2
DewDulligence,
Right you are.
The also talked about an appeal of the CAFC ruling.
Didn't sound like they are thinking about settling any time soon. Might just be bluster only time will tell.
Interesting that they also mentioned the Nashville suit.
Boing X 2
biopearl,
From the AMPH results released tonight.
"During the quarter, net revenues of enoxaparin were $21.3 million, a decrease of 34% compared to $32.0 million for the third quarter of 2014, due to lower average selling prices."
Another 21.3 M in damages to us. Total two quarters 53.3M just last two quarters.
We should have a bond from them now.
Boing X 2
Can now read the patent claims.
FC Construct,
Here is the main part of what appears to be a very complicated patent,
"89. An Fc construct of any one of claims 1 -58 or 75-87 for use in treating an inflammatory or autoimmune or immune disease (e.g., rheumatoid arthritis (RA); systemic lupus erythematosus (SLE); ANCA- associated vasculitis; antiphospholipid antibody syndrome; autoimmune hemolytic anemia; chronic inflammatory demyelinating neuropathy; clearance of anti-allo in transplant, anti-self in GVHD, anti- replacement, IgG therapeutics, IgG paraproteins; dermatomyositis; Goodpasture's Syndrome; organ system -targeted type II hypersensitivity syndromes mediated through antibody-dependent cell-mediated cytotoxicity, e.g., Guillain Barre syndrome, CIDP, dermatomyositis, Felty's syndrome, antibody-mediated rejection, autoimmune thyroid disease, ulcerative colitis, autoimmune liver disease; idiopathic thrombocytopenia purpura; Myasthenia Gravis, neuromyelitis optica; pemphigus and other autoimmune blistering disorders; Sjogren's Syndrome; autoimmune cytopenias and other disorders mediated through antibody-dependent phagocytosis; other FcR-dependent inflammatory syndromes, e.g., synovitis, dermatomyositis, systemic vasculitis, glomerulitis or vasculitis)."
http://worldwide.espacenet.com/publicationDetails/claims?CC=WO&NR=2015168643A2&KC=A2&FT=D&ND=3&date=20151105&DB=worldwide.espacenet.com&locale=en_EP
and patent on Kawasaki Disease,
"51 . A method for treating Kawasaki disease in a subject, said method comprising:
(a) determining the level of one or more proteins in a biological sample obtained from said subject and/or binding of IgG in said sample to one or more proteins comprising an amino acid sequence of any one of SEQ ID NOs:1 to 68 with a kit of any one of claims 40 to 42;
(b) administering a Kawasaki disease therapy if the level of said one or more proteins and/or binding of IgG in said sample is indicative that said subject may benefit from a Kawasaki disease therapy; wherein an increased level of at least one protein of Table 1 , as compared to a reference, and/or a decreased level of at least one protein of Table 2, as compared to a reference, and/or increased binding of IgG in said sample to at least one protein comprising an amino acid sequence of any one of SEQ ID NOs:1 to 68, is indicative that said subject may benefit from a Kawasaki disease therapy.
52. A method for treating Kawasaki disease in a subject, said method comprising:
(a) determining the level of one or more proteins in a biological sample obtained from said subject with a kit of claims 42 or 43;
(b) administering a therapy other than, or in addition to, IVIG therapy if the level of said one or more proteins is indicative that said subject may benefit from a Kawasaki disease therapy other than, or in addition to, IVIG therapy;
wherein an increased level of at least one protein of Table 4, Table 6, and/or Table 8, at least one mRNA of Table 10 or Table 12, and/or at least one glycan of Table 14 or Table 16, as compared to a reference, and/or a decreased level of at least one protein of Table 5, Table 7, and/or Table 9, at least one mRNA of Table 1 1 or Table 13, and/or at least one glycan of Table 15 or Table 17, as compared to a reference, is indicative that the subject may benefit from a Kawasaki disease therapy other than, or in addition to, IVIG therapy.”
http://worldwide.espacenet.com/publicationDetails/claims?CC=WO&NR=2015168602A2&KC=A2&FT=D&ND=3&date=20151105&DB=worldwide.espacenet.com&locale=en_EP
Boing X 2
DewDillgence,
I smiled when he gave us that tidbit. This is a CC that all might want to listen to closely.
Two HSIVig drugs in clinic late 2016.
Orenncia, not as many people involved due to the very complex protein nature of the drug. Presents a better opportunity for us.
Hummira they still feel they can work around all the recent patent discussions.
Going after the finger print on drugs to get the interchangeability rating on all our drugs.
Boing X 2
floblu14,
Another one filed the same day. Appears to be ig FC related vs. just FC
"http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20151105&CC=WO&NR=2015168643A2&KC=A2
COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC CONSTRUCTS”
Boings X 2
t57,
Right you are on all this. I have the feeling we are on track for a great next year.
Boing X 2
floblu14,
Thank you.
I wish 2. had been filled in and the rest of number 3. Cut off before an interesting part.
Boing X 2
t57,
I do like these author’s words in todays article,
"especially since it's unlikely that Novartis, Momenta, and other lower-cost generic drugmakers will fail to capture a larger share of Copaxone sales next year than they do today, or that they'll give up on rolling out a generic 40 mg Copaxone anytime soon.
imnot6 information on Aetna’s Coverage Policy is a good example. I suspect, like regulardoc said, that starting Jan 1st there is going to be some changes. Not long to find out. The genie is out of the bottle.
Boing X 2
t57,
Thank you.
I should have said Judge Moore.
Boing X 2